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a b s t r a c t
Phospholipases A2 (PLA2) are a group of enzymes that hydrolyze phospholipids at the sn-2 position,
being present in all nature. In venomous animals, these proteins assume a special role, being able to
exert diverse pharmacological effects. In this work, authors identiﬁed a new isoform of PLA2 in the
venom of Porthidium hyoprora, which was isolated through sequential chromatographic steps and
named PhTX-III. The enzyme was characterized biochemically and structurally. Structural studies using
mass spectrometry conﬁrmed an acidic secretory PLA2, family IIA, with molecular mass of 13,620.9 Da
and identiﬁcation of 86% of its primary sequence. PhTX-III did not exhibit myotoxic, anticoagulant or
antibacterial effects, often present in this class of enzymes. Although, it was capable of initiate
inﬂammatory response, with local edema and release of cytokines IL-1α, IL-6 and TNF-α, probably due
to mast cell degranulation.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Phospholipases A2 (EC 3.1.1.4), also called PLA2, are a group
of largely studied enzymes that hydrolyze phospholipids at the
sn-2 position, releasing lysophospholipids and fatty acids. In snake
venoms (as well as in other venomous animals) these proteins
present an important hole not only in the digestion process, but
can exhibit several pharmacological effects that will lead to or help
in the capture of prey [20].
The PLA2 are divided into 5 families (cytosolic, secretory,
Caþþ-independent, PAF acetylhydrolases, and the lysosomal)
and 16 major groups. The snake venom PLA2 are comprised into
the secretory phospholipase A2 family (sPLA2), characterized by
the small size (13–18 kDa), tertiary structure with 5–8 disulﬁde
bridges, the presence of histidine in the active site and require-
ment of Caþ þ for catalysis [30,8]. The secreted PLA2 of New World
Viperidae are classiﬁed into group IIA, with a molecular mass
varying between 13 and 15 kDa, seven conserved disulﬁde bridges
and a seven residues C-terminal tail [14,33].
Different isoforms of PLA2 may exhibit one or more different
pharmacological effects (which can happen through direct action
or because of the product of its catalysis) like myotoxicity,
cardiotoxicity, necrosis, anticoagulation, neurotoxicity, cytotoxicity
and others [19,7]. One single species can contain different
isoforms of these molecules, which can be, in some cases, acidic.
Despite of its activity, the acidic PLA2 usually shows weak
neurotoxicity, myotoxicity and lethal potency in vivo, but
induces other signiﬁcant pharmacological effects such as inhi-
bition of platelet aggregation, hypotension, inﬂammatory effects
and cytotoxicity.
The different isoforms found in a snake venom perform
different roles, like prey immobilization or digestion. The differ-
ences in the amino acid sequence and consequent structural
differences will respond for such divergences in activities and
biochemical properties.
Porthidium hyoprora is an endemic species from northwest
region of South America, inside Amazon Forest [5]. Such geogra-
phical isolation may lead to signiﬁcant differences in the biochem-
ical composition of snake venom or speciﬁc proteins. The
evolution process along geographical isolation might origin
different variants of a protein, creating a diversity of pharmacolo-
gical effects, and that would include PLA2s with different char-
acteristics [11].
The structure-function relationship in PLA2 enzymes is not
completely clear for all the effects already reported. It remains an
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unsolved question why some isoforms can perform speciﬁc roles
while others, although very similar, cannot. The lack of some
properties by some phospholipases A2 and the slight differences in
their structures are clues to understand how such toxins act [6].
In the present work, a new acidic PLA2, called PhTX-III, was
isolated from Porthidium hyoprora venom and characterized in its
structure, biochemistry and pharmacological properties, in an
effort to comprehend more about this class of enzymes.
2. Material and methods
2.1. PhTX-III obtaining
Porthidium hyoprora crude venom (Sigma-Aldrich Chemical Co.;
St. Louis, MO, USA) was puriﬁed through two chromatographic
steps. First, 50 mg of crude venom was dissolved in 1 ml of
Ammonium bicarbonate buffer (AMBIC) 1 M, pH 8.0 and then
centrifuged at 9000g for 5 min. The supernatant was submitted to
gel ﬁltration chromatography using Sephadex G75 column
(1.5 cm100 cm), previously equilibrated with AMBIC 50 mM,
under a ﬂow rate of 12 ml/h. The PLA2 active pool was selected,
lyophilized and 5 mg of it was dissolved in 120 μl of 0.1% (v/v)
triﬂuoroacetic acid (solvent A) and 80 μl of AMBIC. The solution
was again centrifuged at 9000g for 5 min and the supernatant was
submitted to a reverse phase chromatography in a C5 Supelco
(0.7830 cm) column previously equilibrated with Solvent A.
Samples were eluted with a linear gradient (0–100%, v/v) of
acetonitrile 66% (solvent B) at a constant ﬂow rate of 1.0 ml/min
over 70 min. The elution proﬁle was monitored at 280 nm, and the
collected fractions were lyophilized and conserved at 20 1C
(Fig. 1A). All chemicals and reagents were of analytical or
sequencing grade.
2.2. PLA2 activity
PLA2 activity was measured using the assay described by Cho
and Kezdy [4] and Holzer and Mackessy [15]. The standard assay
mixture contained 200 μL of buffer (10 mM Tris–HCl, 10 mM CaCl2
and 100 mM NaCl, pH 8.0), 20 μL of substrate 4-nitro-3-(octanoy-
loxy) benzoic acid (3 mM), 20 μL of water and 20 μL of the testing
sample in a ﬁnal volume of 260 μL. The mixture was incubated for
up to 40 min at 37 1C, and absorbance was monitored at every
10 min. The enzyme activity, expressed as the initial velocity of the
reaction (V0), was calculated based on the increase of absorbance
after 20 min.
2.3. PhTX-III kinetic parameters
For evaluation of different conditions in PLA2 activity, the
above-described assay was performed with only punctual changes
in the desired parameter. For temperature evaluation, the assay
was performed varying temperature from 25 1C to 45 1C. The pH
inﬂuence over activity was evaluated using different buffers:
Sodium citrate buffer (pHs 4.0–5.0); Tris–HCl buffer (6.0–8.0);
glicine buffer (9.0–10.0). The inﬂuence of divalent ions in reaction
was performed either by substituting the Ca2þ by Ba2þ , Zn2þ ,
Mn2þ or Mg2þ , or adding these ions and reducing the amount of
calcium from 10 mM to 1 mM. Inﬂuence of substrate concentration
was measured by varying 4-nitro-3-(octanoyloxy) benzoic acid
concentration from 0.05 to 10 mM.
2.4. Molecular mass determination by mass spectrometry
An aliquot (45 μL) of the PhTX-III was injected into a C18
column (100 μm100 μm) in a RP-UPLC (nanoAcquity UPLC,
Waters). The UPLC was coupled with nanoelectrospray tandem
mass spectrometry on a Q-T of Ultima API mass spectrometer
(MicroMass/Waters) at a ﬂow rate of 600 nl/min. The gradient was
0–50% acetonitrile in 0.1% formic acid over 45 min. The instrument
was operated in MS continuum mode and the data acquisition was
fromm/z 100 to 3000 at a scan rate of 1 s and an interscan delay of
0.1 s. The spectra were accumulated over about 300 scans and the
multiple charged data produced by the mass spectrometer on the
m/z scale were converted to the mass (molecular weight) scale
using maximum-entropy-based software supplied with Masslynx
4.1 software package. The processing parameters were: output
mass range 6000–20,000 Da at a “resolution” of 0.1 Da/channel;
the simulated isotope pattern model was used with the spectrum
blur width parameter set to 0.2 Da and the minimum intensity
ratios between successive peaks were 20% (left and right). The
deconvoluted spectrum was then smoothed (23 channels,
Savitzky Golay smooth) and the mass centroid values obtained
using 80% of the peak top and a minimum peak width at half
height of four channels.
2.5. Tryptic digestion and analysis
The protein was reduced with DTT (in a ﬁnal concentration of
5 mM) for 25 min at 56 1C and alkylated with Iodoacetamide (in a
ﬁnal concentration of 14 mM) for 30 min prior to the addition of
trypsin (Promega's sequencing grade modifed). After trypsin
addition (20 ng/μL in ammonium bicarbonate buffer 0.05 M), the
Fig. 1. (A) Elution proﬁle of a reverse phase chromatography of the selected pool from gel ﬁltration (pool II), using Supelco C5 column. In gray, the selected fraction, PhTX-III.
(B) Deconvoluted Maldi-TOF mass spectrum of PhTX-III used to determine exact protein mass and attesting homogeneity of sample.
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sample was incubated for 16 h at 37 1C. To stop the reaction, formic
acid 0.4% was added and the sample centrifuged at 2500 rpm for
10 min. The pellet was discarded and the supernatant dried in a
speed vac. The resulting peptides were separated by C18
(100 mm100 mm) RP-UPLC (nanoAcquity UPLC, Waters) coupled
with nanoelectrospray tandem mass spectrometry on a QTof
Ultima API mass spectrometer (MicroMass/Waters) at a ﬂow rate
of 600 nl/min. Before performing a tandem mass spectrum, an
ESI/MS mass spectrum (TOF MS mode) was acquired for each HPLC
fraction over the mass range of 100–2000m/z, in order to select
the ion of interest; subsequently, these ions were fragmented in
the collision cell (TOF MS/MS mode). Raw data Files from LC–MS/
MS runs were processed using Masslynx 4.1 software package
(Waters) and analyzed using the MASCOT search engine version
2.3 (Matrix Science Ltd.) against the snakes database, using the
following parameters: peptide mass tolerance of 70.1 Da, frag-
ment mass tolerance of 70.1 Da, and oxidation as variable
modiﬁcations in methionine and trypsin as enzyme.
2.6. Miotoxicity evaluation
Swiss male mice (18–20 g; n¼5) received an intramuscular
(i.m.) or an intravenous (i.v.) injection of 20 mg of PhTX-III in
phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium
phosphate, pH 7.2) in a total volume of 50 ml. The i.m. group
received the injection in the gastrocnemius muscle and the i.v.
group in the tail vein. Control groups received only PBS. Blood was
collected from the tail into heparinized capillary tubes after two
hours and the plasmatic creatine kinase (CK; EC 2.7.3.2) activity
was determined by a kinetic assay Ck-Nac, (creatine kinase, Beacon
Diagnostics, Germany). The results were expressed as U/L accord-
ing to the manufacturer.
2.7. Antibacterial activity
The antibacterial capacity of PhTX-III was tested using agar
diffusion test, according to Bauer (1966). Six bacteria strains were
used: Escherichia coli (E. coli ATCC 25922), Pseudomonas aeruginosa
(P. aeruginosa ATCC 27853; P. aeruginosa 31NM) and Staphylococcus
aureus (S. aureus ATCC 25923; S. aureus BEC9393; S. aureus Rib1).
Commercially available antibiotics Oﬂoxacin and Imipinen were
used as positive controls. The isolated PLA2 was tested in crescent
doses until 200 mg/ml.
2.8. Anticoagulant activity
Swiss male mice blood was used in the two different antic-
oagulant tests. Activated partial thromboplastin time (aPTT) and
the prothrombin time (PT) tests. The blood was collected by
cardiac puncture in 3.8% citrate-contained tubes in a volume ratio
of 9:1. Blood was centrifuged and only plasma used in the tests.
The volume of plasma used in the experiments was 45 ml with 5 ml
of toxin solution. Control tests used 50 ml of plasma. Both tests
used commercially available kits and automatic coagulometer.
2.9. Rat paw edema induction
Swiss male mice (18–20 g; n¼5) received subplantar injections
from 5 to 40 μg of PhTX-III in PBS; in a total volume of 50 ml.
Control groups received only the PBS. The paw swelling was
measured with an Electronic Caliper Series 1101 (INSIZE LTDA,
SP, Brazil) at 0.5, 3, 6, and 24 h after administration. Edema was
expressed as the percentual increase in the size of the treated
group compared to the control group at each time. Minimal
edematogenic dose was deﬁned as the dose necessary to cause
an increase of 30% in paw size.
2.10. Cytokines quantiﬁcation
Swiss male mice (18–20 g; n¼5) were injected a 10 mg dose of
PhTX-III in the tibial muscle. Afterwards, blood samples were
collected from the animals at different times using heparinized
capillaries to check the plasma cytokines proﬁle over time. Inter-
leukin 1α (IL-1α), interleukin 6 (IL-6), and tumor necrosis factor
alpha (TNF-α) concentrations were determined using commer-
cially available ELISA kits (BD OptEIA, BD Biosciences) following
provided instructions.
2.11. Morphological analysis
Swiss male mice (18–20 g; n¼5) gastrocnemius muscles were
injected 10 μg of PhTX-III dissolved in PBS, in a total volume of
50 μl or only PBS buffer (control). After one hour, the animals were
euthanized by cervical dislocation and had the muscles removed
and ﬁxed with formaldehyde 10% solution in Millonig's buffer
(0.13 M sodium phosphate, 0.1 M NaOH, pH 7.4) for twelve hours
at 4 1C. After that, the injected muscles were washed in water,
ethanol dehydrated, diaphanized with xylene and parafﬁn-
embedded. Longitudinal and transversal sections of 7 mm were
stained by hematoxylin–eosin (HE) and Dominici staining and
were analyzed under a Carl Zeiss Axio Scope.A1 light microscope.
Photographs were obtained using Carl Zeiss AxioCam ICc3.
Modiﬁed Dominici staining was performed based on Litt [22].
Sections were stained in a mixture of Acid fucsin and Orange G for
30 min. After a quick rinse in ethanol 60%, they were stained in
Toluidine blue 0.75% for 20 s. Solutions were prepared according
to Tolosa [35].
3. Results
3.1. Enzyme structure studies
The mass spectrometry attested the toxin homogeneity after
puriﬁcation and revealed its exact molecular mass as 13,620.9 Da
(Fig. 1B).
The peptides obtained by the tryptic digestion were submitted
to MS/MS analysis, and the raw data were processed using Mascot
MS/MS Ion Search software. It was possible to obtain 86% of the
PhTX-III primary structure. The protein had its structure partially
deduced by comparison with other proteins which data was
already available in databases (NCBI and UniProt). Through such
comparisons, it was possible to align the primary structure of
PhTX-III with other similar PLA2, revealing great similarity with
other toxins from different snake venoms (Fig. 2). The alignment
was performed using Clustal Omega [13,32,25].
Some notable residues are present in the sequence: The
calcium binding loop, comprehended between residues 25 and
33, Y–G–C–Y–C–G–X–G–G (being X a serine substitution in PhTX-
III); the fragment C–C–F–V–H–D–C–C–Y–G–K, highly conserved in
the PLA2, between residues 43 and 53, which contains part of the
active site: H48, D49, Y52, D99.
The techniques applied revealed a protein with high identity
with other already characterized PLA2 (up to 75% identity), all of
them isolated from snake venoms, acidic and containing 122
aminoacids. That is a strong indication that PhTX-III is an acidic
PLA2, which was later conﬁrmed by prediction of the isoelectric
point, estimated as 5.04, using the software EMBOSS Pepstats
[13,25,28,32].
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3.2. Enzymatic and biological activities
The PhTX-III presents phospholipolytic activity against the
chromogenic substrate 4-nitro-3-(octanoyloxy) benzoic acid. The
optimal temperature and pH are 37 1C (Fig. 3A) and 8.0 (Fig. 3B),
respectively. The maximum velocity obtained by the substrate
concentration studies was 10.81 U, with a Km of 4.43 mM. The
enzyme is dependent of calcium ions to work properly and
incubation with other divalent ions leads to loss of catalytic
activity. Among the tested ions, magnesium-containing medium
retained around 75% of the enzyme activity, and that is the best
result. Zinc totally inhibits any trace of enzymatic activity (Fig. 3D).
The maximum tested dose of 20 mg of the PhTX-III, do not
exhibit myotoxicity or anticoagulant activity. The intramuscular
and intravenous injections do not lead to increases in the plasma
CK content, which would indicate muscular lesion. The protein is
also unable to exert any antibacterial activity even at very high
doses, up to 200 mg/ml.
As stated, the studied toxin does not show anticoagulant effect.
In the PT test, the clothing time was 20.9771.33 in the control
group and 21.572.69 in PhTX-III presence. For the aPTT test, the
coagulation times were 33.1773.03 and 37.171.65 in control
group and with toxin added, respectively. In both cases, there
was no statistical difference.
PhTX-III exhibited intense inﬂammatory effect evaluated by
cytokine analysis and moderate edema formation subsequent to
footpad injection. The edematogenic effect was monitored in the
course of 24 h and revealed a dose-dependent relationship in the
edema size and persistency. The minimal edematogenic dose
found was 5 μg, which caused a 30% increase in the paw size after
one hour. In this same time, the 20 and 40 μg doses caused 39%
and 51% in size increase, respectively (Fig. 4). The lower doses do
not show any signs of edema after 24 h, but in the higher one, the
edema persisted, with paw size increased by 27%.
Thirty minutes after the toxin injection, the levels of inﬂam-
matory cytokines IL-1α, IL-6 and TNF-α started to exhibit a
different proﬁle compared with the control mice, injected with
PBS. TNF-α peaked one hour after toxin injection (reaching
2496.357210.54 U/ml), but its concentration dropped quickly,
standing close to basal levels after 3 h. IL-6 levels started to
increase after 0.5 h, reaching its peak of 108.6572.41 pg/ml at
3 h. After that, its concentration started to decrease reaching basal
levels after 12 h. IL-1α concentration rose one hour after toxin
injection, and kept its behavior until 6 h, where it reached a
maximum concentration that was persistent until 12 h (Fig. 5). The
cytokines concentration increase is another evidence of the
inﬂammatory properties of PhTX-III.
The histological sections in the muscles injected with PBS
buffer or PhTX-III conﬁrmed that the toxin do not cause muscle
damage, conﬁrming by the CK analysis. The muscle integrity was
clear in both cases. The difference observed is the great amount of
inﬂammatory inﬁltrate present in the toxin-injected muscles, with
large number of leukocytes. Dominici staining made possible the
identiﬁcation of these cells as mastocytes (Fig. 6).
4. Discussion
In a constant effort to unveil the relationship between structure
and function of the PLA2, our group isolated a novel acidic isoform
from the venom of Porthidium hyoprora, with high catalytic activity
but unable to exert myotoxic, anticoagulant or antibacterial
activities.
After the PhTX-III isolation, the primary structure studies
identiﬁed it as a group IIA PLA2 [30]. The comparison of the partial
primary structure with other PLA2 attested up to 75% of identity
with acidic isoforms of that enzyme from different snake species
venoms (Fig. 2). If observed properly in Fig. 2, the conserved
residue sequences start and ﬁnish always one amino acid earlier
than the usual by these enzymes. This happens due to a deletion of
a residue, early in the chain, and it happens with frequency in the
acidic group IIA PLA2, nevertheless the usual numbering is used in
order to describe the conserved regions [37,39,29]. This observa-
tion, along with the prediction of the isoelectric point, is another
indication that the enzyme is acidic.
The phospholipolytic activity of PhTX-III was evaluated using
the synthetic substrate 4-nitro-3-(octanoyloxy) benzoic acid and
the values of optimal temperature and pH found were 37 1C and
8.0, respectively, which are very common and typical values for
these enzymes [36,2,10,16,17,27]. Comparing PhTX-III activity in a
Fig. 2. (A) Aligning and comparison of PhTX-III obtained peptides with other acidic PLA2 from snake venoms. All the molecules compared are acidic PLA2, isolated from
snakes: Bothrops diporus (UniProt I2DAL4; UniProt I2DAL5), Bothrops erythromelas (UniProt Q2HZ28), Trimeresurus gramineus (UniProt P81479; P81480) Bothrops pictus
(UniProt Q9I8F8). The asterisk (*) means full consensus for that residue, colon (:) means partial consensus. The acidic residues are marked in red.
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medium containing calcium, different divalent ions cannot sup-
port enzymatic activity properly. Other divalent ions seem to
compete for the calcium binding site, and those with more similar
ionic radii, like Zn2þ tend to cause more effective inhibition [40].
It is usual to ﬁnd snake venom acidic PLA2 with an only mild
presence of pharmacological effects or totally missing them
[18,9,38]. PhTX-III lacks some pharmacological properties tested,
usually presented by its basic counterparts. Even at high doses,
PhTX-III is not able to exert myotoxic, anticoagulant or antimicro-
bial activities.
The region predicted to be responsible for the myotoxic effects
of PLA2, comprehended between residues 79 and 87 contains
negatively charged aminoacids and a very small amount of
positive charges in PhTX-III. Kini and Evans [20] afﬁrmed based
on observation of several myotoxic phospholipases A2, that this
region must usually contain a great amount of positively charged
residues in order to cause myotoxicity. Similarly, the enzyme site
considered fundamental for the observation of antibacterial
effects, must be rich in basic aminoacids. This area, the C-
terminal region of the PLA2, contains several negatively charged
residues, which is probably the responsible for its lack of anti-
bacterial activity.
Even with absence of some classical pharmacological effects,
PhTX-III exhibits intense inﬂammatory properties, with formation
Fig. 3. PhTX-III activities under different circumstances. (A and B) Effect of temperature and pH over enzyme activity, respectively. (C) Effect of substrate concentration over
PhTX-III using chromogenic substrate 4-nitro-3-(octanoyloxy)benzoic acid. (D) Effects of different divalent ions over PhTX-III activity, with or without addition of Caþ2.
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of edema and increase in plasma concentration of acute phase
inﬂammatory cytokines (Figs. 4 and 5). Edemas are caused by
microvascular permeability increase and appear after 1 h of
PhTX-III injection in the mice paw. The edemas can be induced
by arachidonic acid, resulting from the phospholipase A2 catalysis,
and by the release of IL-1 [1,31].
Huancahuire-Vega et al. [17] studying another PLA2 of the same
venom, PhTX-I, veriﬁed its capacity of elevating IL-6 plasma
concentration, with a peak of 95 pg/ml after 3 h after injection.
PhTX-III causes a peak of the cytokine at the same time after
injection, but with more pronounced IL-6 release, of 147 pg/ml.
Other authors obtained similar results with different inﬂam-
matory capable PLA2 from different sources. In those, the cytokines
serum concentrations peaked around three hours after toxin
injection, same as in the present paper, but with less intensity
[23,2].
Research using a PLA2 isolated from Bothrops roedingeri
revealed high inﬂammatory capabilities, with a similar behavior
[12]. As stated by the researcher, TNF-α, is likely to be induced
by PLA2 action, which would induce the expression of selec-
tins resulting in release of other interleukins, such as IL-1 and
IL-6.
Histological observations in the toxin-injected tissues reveal no
muscle damage, but great amount of inﬂammatory inﬁltrate, with
large number of cells. Dominici staining made possible the
identiﬁcation of these as mast cells, as suspected by previous
observations in sections stained with HE. Since there was no tissue
damage or hemorrhage caused by PhTX-III, the source of cytokines
can be explained by mast cell degranulation [12,34].
Some phospholipases A2 can act on blood cells, including
neutrophils [24], macrophages [41] and induction of mast cell
degranulation [3,21]. As mentioned in Section 1, many pharmaco-
logical effects caused by PLA2 requires catalytic activity or the
presence of positive charges in its surface, in order to interact
with the target, and mast cell degranulation is no exception to this
rule [26].
Based on the stated results, at least part of the inﬂammatory
manifestations can be due to mast cell degranulation, caused by
the action of PhTX-III. Although PhTX-III is an acidic enzyme, it still
contains positively charged residues, in a lower proportion.
Further studies of activities and structure comparison with other
PLA2, basics and acids, can lead to future clues about what is the
speciﬁc site of interaction between PLA2 and mast cells.
Fig. 4. Edema-forming activity in mice pawn after PhTX-III injection. Results are
shown in percentage of increase of the hind pawn after application of different
concentrations of toxin, from 0.5 to 24 h. The determined minimal edematogenic
dose was 5 mg.
Fig. 5. Plasmatic concentration of cytokines IL-1α (pg/ml), IL-6 (pg/ml) and TNF-α
(U/ml) along 12 h after toxin injection. Empty markers represent measurements
made in the control group and ﬁlled markers, the group that received PhTX-III.
Fig. 6. Sections of the gastrocnemius muscles from mice injected with PhTX-III or phosphate buffer, where: A, B, C – HE stained muscle section, injected with phosphate
buffer (A) and PhTX-III (B and C). D, E, F – Dominici stained muscle section, injected with phosphate buffer (D) and PhTX-III (E, F). Bar in A, B: 40 μm. Bar in C, D, E, F: 20 μm.
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